Martin Voss, MD, reviews data updates from ASCO GU 2024 on the KEYNOTE-B61 study of lenvatinib + pembrolizumab in nccRCC in addition to real-world outcomes in patients with chromophobe RCC.
Gemcitabine Intravesical System Combo Shows High pCR Rate in MIBC
Updated results from SunRISe-4 support further investigation of the gemcitabine intravesical system plus cetrelimab in MIBC.
Exploring the ESMO 2025 Presentations That May Shift GU Oncology
Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.
Perioperative Durvalumab/NAT Chemo Does Not Improve HRQOL in MIBC
New findings reveal that adding durvalumab to neoadjuvant chemotherapy does not enhance HRQOL in muscle-invasive bladder cancer patients.
Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC
Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.
Atezolizumab Did Not Improve EFS in Non–Muscle-Invasive Bladder Cancer
The safety profile of the atezolizumab with Bacillus Calmette-Guérin in NMIBC was consistent with that of each individual agent.
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
Anticipated data from the ESMO Congress 2025 may have implications for standards of care across prostate and bladder cancer groups.